Experience

Davis Polk advised the sole underwriter in connection with the public offering of 3,450,000 shares of common stock of NanoString Technologies, Inc. The common stock is listed on the NASDAQ…

Davis Polk advised the joint book-running managers in connection with the $112.5 million public offering of common stock of Achaogen, Inc. The common stock is listed on the NASDAQ…

Davis Polk advised the sole book-running manager of a $359.35 million SEC-registered offering of 5,000,000 shares of common stock of Alnylam Pharmaceuticals, Inc. Alnylam’s common stock is…

Davis Polk advised the representative of the several underwriters in connection with a secondary offering of 7,000,000 shares of Class A common stock of Evolent Health, Inc. by certain of…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by DexCom, Inc. of $350 million aggregate principal amount of its 0.75% senior convertible notes due…

Davis Polk advised the underwriters in connection with an SEC-registered offering by AMAG Pharmaceuticals, Inc. of $300 million aggregate principal amount of its 3.25% convertible…

Davis Polk advised the joint book-running managers in connection with a $2.25 billion registered offering by Eli Lilly and Company of $750 million principal amount of its 2.350% notes…

Davis Polk advised the representative of the initial purchasers in a Rule 144A offering by Flexion Therapeutics, Inc. of $201.25 million aggregate principal amount of its 3.375% convertible…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 5,050,505 shares of common stock of…

Davis Polk advised the sole book-running manager in connection with Galapagos NV’s offering of 4,312,500 ordinary shares in the form of American depositary shares, which includes the full…